- Raised $450k funding round, May 2023
- Raised funding round, Aug 2023
- Raised funding round led by NGT3, Aug 2021
About
INTRAGEL is a research-driven company dedicated to pioneering an advanced treatment for solid tumors using our state-of-the-art gel-based drug delivery technology. The SRGel platform enables local and prolonged release of a wide range of anti-cancer medications offering new life-changing cancer treatment options.
The SRGel platform is revolutionizing cancer treatment by enabling local sustained release of anticancer drugs at the tumor site, to maximize therapeutic effectiveness while minimizing systemic exposure and adverse effects. Built on natural and safe fatty acids, its unique hydrophobic, biocompatible and biodegradable gel-based composition is a true breakthrough in drug delivery. As an injectable pre-filled single syringe, SRGel is easy to use, ready to be placed in any solid tumor, including surgically inaccessible tumors and/or chemo/radio-resistant tumors.
SRGel has successfully been combined with cisplatin, its flagship product, TumoCure, to treat head and neck, and lung cancer. Other drugs, such as paclitaxel and temozolamide, have also been successfully combined to treat other tumors. Future products in development aim to address other unmet medical needs in, colorectal, ovarian, and testicular cancer.
Funding history · 3 rounds · $450K total
Q&A
- What is IntraGel Therapeutics' primary focus?
- IntraGel Therapeutics is a research-driven company focused on pioneering advanced treatments for solid tumors using its SRGel platform, a gel-based drug delivery technology.
- What is the purpose of IntraGel Therapeutics' SRGel platform?
- The SRGel platform aims to revolutionize cancer treatment by enabling local, sustained release of anti-cancer drugs directly at the tumor site, maximizing therapeutic effectiveness while minimizing systemic exposure and adverse effects.
- What is IntraGel Therapeutics' flagship product?
- IntraGel Therapeutics' flagship product is TumoCure, which combines the SRGel platform with cisplatin to treat head and neck, and lung cancer.
- What types of cancer are IntraGel Therapeutics' future products aiming to address?
- Future products in development by IntraGel Therapeutics aim to address unmet medical needs in colorectal, ovarian, and testicular cancer.
- How many employees does IntraGel Therapeutics have?
- IntraGel Therapeutics has 1-10 employees.
- When was IntraGel Therapeutics founded?
- IntraGel Therapeutics was founded in December 2020.
- What is IntraGel Therapeutics' total amount raised to date?
- IntraGel Therapeutics has raised a total of $450,000 USD.
- Which investors participated in IntraGel Therapeutics' funding round in May 2023?
- In May 2023, IntraGel Therapeutics received funding from Israel Innovation Authority and NGT HealthCare II.
- What is the current product stage of IntraGel Therapeutics?
- IntraGel Therapeutics is in the clinical trial product stage.
Team · 3
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | intra-gel.com |
|---|---|
| linkedin.com/company/72377575 | |
| facebook.com/IntraGel-Therapeutics-103823218528283 |
Identifiers & details
| Founded | 2020-12 |
|---|---|
| Employees (exact) | 6 |
Radar intelligence
Patents
| EPO | 2 |
|---|
Web history (Wayback)
| Domain | intra-gel.com |
|---|
Certificate / subdomain footprint
| Subdomains | 1 |
|---|